In castration-resistant prostate cancer, inhibition of androgen receptor (AR) induces HR defects and confers PARPi sensitivity (127, 128), suggesting that AR signaling promotes cancer cell survival by enhancing HR. The gene discussed is AR; the disease is cancer.